• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Medical Officer Jordan Julie was granted 8,400 shares (SEC Form 4)

    3/28/25 9:28:27 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NGNE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Jordan Julie

    (Last) (First) (Middle)
    C/O NEUROGENE INC.
    535 W 24TH STREET, 5TH FLOOR

    (Street)
    NEW YORK NY 10011

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Neurogene Inc. [ NGNE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Medical Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    03/26/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/26/2025 A 8,400(1) A $0 8,400 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Employee Stock Option (Right to buy) $16.14 03/26/2025 A 50,300 (2) 03/26/2035 Common Stock 50,300 $0 50,300 D
    Explanation of Responses:
    1. Consist of 8,400 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
    2. This option represents the right to purchase 50,300 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.
    Remarks:
    /s/ Christine Mikail, as attorney-in-fact for Julie Jordan 03/28/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $NGNE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NGNE

    DatePrice TargetRatingAnalyst
    6/17/2025$50.00Buy
    Craig Hallum
    5/16/2025$24.00Outperform → Neutral
    Robert W. Baird
    6/27/2024$65.00Outperform
    BMO Capital Markets
    6/11/2024$54.00Outperform
    Robert W. Baird
    4/29/2024$46.00Outperform
    Leerink Partners
    3/21/2024$61.00Outperform
    William Blair
    More analyst ratings

    $NGNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Samsara Biocapital Gp, Llc bought $1,259,623 worth of shares (48,770 units at $25.83) (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/27/24 4:39:29 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CFO Cvijic Christine Mikail bought $491,400 worth of shares (24,000 units at $20.48), increasing direct ownership by 45% to 76,844 units (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/25/24 9:29:29 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Mcminn Rachel bought $969,000 worth of shares (47,500 units at $20.40), increasing direct ownership by 4% to 1,297,859 units (SEC Form 4)

    4 - Neurogene Inc. (0001404644) (Issuer)

    11/25/24 9:29:04 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025

    Completed discussions with FDA on registrational protocol; 13 sites to allow for rapid enrollment New preclinical data at ESGCT Congress highlight NGN-401 best-in-class potential and add to body of evidence that ICV administration is superior to IT-L in reaching key brain regions underlying Rett syndrome As previously reported, the first four participants in the NGN-401 Phase 1/2 trial gained 23 developmental milestones/skills, representing multi-domain improvement that requires transduction of key brain regions and nervous system The preclinical data also provide evidence-based confirmation that ICV and IT-L administration result in comparable peripheral organ transduction, showing n

    10/9/25 7:00:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference. Format: Management will participate in a fireside chat and investor meetings Date: Tuesday, October 14 at 7:00 a.m. ET A webcast of the fireside chat will be accessible from the Investor Relations section of Neurogene's website under events, where a replay of the event will also be available for a limited time. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to imp

    10/8/25 7:30:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 9,390 shares of the Company's common stock to four new employees (the "Inducement Grants") on October 1, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance w

    10/3/25 4:01:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Baffi Robert

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:07:42 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Woods Robert Keith

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:07:13 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Palekar Rohan

    4 - Neurogene Inc. (0001404644) (Issuer)

    6/13/25 12:06:44 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Neurogene with a new price target

    Craig Hallum initiated coverage of Neurogene with a rating of Buy and set a new price target of $50.00

    6/17/25 8:10:28 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Neurogene from Outperform to Neutral and set a new price target of $24.00

    5/16/25 8:03:18 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BMO Capital Markets initiated coverage on Neurogene with a new price target

    BMO Capital Markets initiated coverage of Neurogene with a rating of Outperform and set a new price target of $65.00

    6/27/24 7:50:19 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    SEC Filings

    View All

    Neurogene Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Neurogene Inc. (0001404644) (Filer)

    10/9/25 7:01:21 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Neurogene Inc.

    SCHEDULE 13G/A - Neurogene Inc. (0001404644) (Subject)

    8/14/25 4:27:25 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Neurogene Inc.

    424B5 - Neurogene Inc. (0001404644) (Filer)

    8/11/25 4:48:06 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Leadership Updates

    Live Leadership Updates

    View All

    Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

    Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome. As previously disclosed, on November 11, 2024, Neurogene became aware of an emerging treatment-related serious adverse event (SAE) in a trial participant who received NGN-401 at a dose of 3E15 vg (high-dose cohort). This participant, who was dosed on November 5, subsequently experienced signs of a systemic hyperinflammatory syndrome, a rare and life-threatening immune response tha

    11/18/24 6:45:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates

    Expanded Phase 1/2 gene therapy trial for Rett syndrome to inform future registrational study design; Company remains on track to share interim clinical data in 4Q:24 Strong financial position with runway into 2H:26 following reverse merger and private financing in December 2023 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced fourth quarter and full year 2023 financial results and highlighted recent corporate updates. "We started the year with strong execution in our Phase 1/2 NGN-401 gene therapy trial for female pediatric patients with Rett syndrom

    3/18/24 4:14:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Neurogene Inc.

    SC 13G - Neurogene Inc. (0001404644) (Subject)

    12/11/24 4:05:09 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

    SC 13G/A - Neurogene Inc. (0001404644) (Subject)

    11/27/24 4:25:10 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neurogene Inc.

    SC 13G/A - Neurogene Inc. (0001404644) (Subject)

    11/14/24 4:53:08 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NGNE
    Financials

    Live finance-specific insights

    View All

    Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome

    All participants experienced a 2-point improvement in the clinician-rated Clinical Global Impression-Improvement (CGI-I) scale from baseline All participants improved in the caregiver-completed Rett Syndrome Behavior Questionnaire (RSBQ), ranging from 28 to 52 percent improvement from baseline All participants with disruptions in sleep, constipation, and dysphagia at baseline demonstrated objective improvements Gains in skill and developmental milestones were consistent, durable, deepened over time and demonstrated improvements not expected based on natural history data Low-dose NGN-401 well-tolerated with favorable safety profile Company plans to provide an update of registration

    11/11/24 4:01:00 PM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

    Company to host webcast to review data on November 11 at 4:30 p.m. ET Late-breaker poster to be presented during Child Neurology Society Meeting on November 12 Neurogene Inc. (NASDAQ:NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will also be shared. These data will also be presented in a late-breaking

    10/21/24 7:30:00 AM ET
    $NGNE
    Biotechnology: Pharmaceutical Preparations
    Health Care